PET imaging of the anticancer drug candidate [11C]trimebutine in a rat glioma model
Trimebutine exhibits inhibitory effects on the growth and migration of glioma cells in a dose- and time-dependent manner. [<sup>11</sup>C]Trimebutine was able to penetrate the blood-brain barrier in rats and tracer uptake could be significantly reduced by administration of a μ-opioid receptor antagonist. However, [<sup>11</sup>C]trimebutine failed to selectively accumulate in orthotopic C6 glioma, which could be caused by low expression levels of the drug target in these tumors, or by fast metabolism of the tracer.
Authors
- Erik F. J. de Vries (ORCID: https://orcid.org/0000-0002-6915-1590)
- Jia‐zhe Lin (ORCID: https://orcid.org/0000-0002-2101-6357)
- Maria Kominia
- Janine Doorduin (ORCID: https://orcid.org/0000-0003-2925-9959)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Shantou University (CN)
- First Affiliated Hospital of Shantou University Medical College (CN)
Publication Details
- Journal
- Nuclear Medicine and Biology
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1016/j.nucmedbio.2024.108985
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Rijksuniversiteit Groningen
- Universitair Medisch Centrum Groningen